We are live on ! Find out more
FBIO icon

Fortress Biotech

50 hedge funds and large institutions have $6.43M invested in Fortress Biotech in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 11

24% more call options, than puts

Call options by funds: $92K | Put options by funds: $74K

3% more capital invested

Capital invested by funds: $6.21M → $6.43M (+$213K)

0% more funds holding

Funds holding: 5050 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

1.16% less ownership

Funds ownership: 17.76%16.6% (-1.2%)

Holders
50
Holders Change
Holders Change %
0%
% of All Funds
0.72%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
23
Reduced
11
Closed
5
Calls
$92K
Puts
$74K
Net Calls
+$18K
Net Calls Change
-$7K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$903K +$156K +82,000 +15%
Cambridge Investment Research Advisors
2
Cambridge Investment Research Advisors
Iowa
$801K +$886K +465,500 +524%
RA
3
Rosalind Advisors
Ontario, Canada
$727K -$200K -104,969 -17%
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$696K +$391K +205,087 +74%
PAM
5
PVG Asset Management
Colorado
$540K +$415K +218,115 +140%
SAM
6
Shikiar Asset Management
New York
$342K +$19K +10,000 +4%
Envestnet Asset Management
7
Envestnet Asset Management
Illinois
$266K +$141K +73,892 +67%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$244K +$71.9K +37,736 +29%
NCM
9
Nantahala Capital Management
Connecticut
$221K
BlackRock
10
BlackRock
New York
$160K +$2.04K +1,071 +1%
Corient Private Wealth
11
Corient Private Wealth
Florida
$145K
GCP
12
GSA Capital Partners
United Kingdom
$118K -$216K -113,505 -58%
Renaissance Technologies
13
Renaissance Technologies
New York
$113K +$149K +78,088 New
AI
14
Atria Investments
North Carolina
$103K +$50.2K +26,351 +58%
1WA
15
180 Wealth Advisors
Washington
$98.7K +$11.3K +5,950 +10%
Commonwealth Equity Services
16
Commonwealth Equity Services
Massachusetts
$89K -$388 -204 -0.3%
HWM
17
HB Wealth Management
Georgia
$80K +$105K +55,333 New
IWC
18
Integrated Wealth Concepts
Massachusetts
$66.6K +$35.6K +18,700 +68%
Northern Trust
19
Northern Trust
Illinois
$59.8K -$9.11K -4,785 -10%
TAM
20
Titleist Asset Management
Texas
$56.4K -$2.06K -1,080 -3%
CL
21
Choreo LLC
Illinois
$51.8K
Citadel Advisors
22
Citadel Advisors
Florida
$51.4K +$50K +26,268 +283%
Prudential Financial
23
Prudential Financial
New Jersey
$45.6K +$18.7K +9,800 +45%
Wealth Enhancement Advisory Services
24
Wealth Enhancement Advisory Services
Minnesota
$44.1K -$38.6K -20,266 -40%
Fidelity Investments
25
Fidelity Investments
Massachusetts
$38.2K +$3.44K +1,806 +7%

FBIO Hedge Fund Activity: Q3 2024 in Review

50 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q3 2024, worth a combined $6.43M — up 3.4% from $6.21M a quarter earlier.

Fund positioning in FBIO was balanced in Q3 2024: 5 funds opened new positions, 5 closed out, 23 added to existing stakes and 11 trimmed.

The largest buyer was Cambridge Investment Research Advisors, adding an estimated $886K. The largest seller was GSA Capital Partners, cutting an estimated $216K.

  • 50 institutional investors held Fortress Biotech (FBIO) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $6.43M of Fortress Biotech stock for Q3 2024, up 3.4% quarter-over-quarter.
  • 5 funds opened new Fortress Biotech positions in Q3 2024 and 5 closed out, a net change of 0 holders.
  • The largest Fortress Biotech buyer in Q3 2024 was Cambridge Investment Research Advisors, an estimated $886K added.
  • The largest Fortress Biotech seller in Q3 2024 was GSA Capital Partners, an estimated $216K sold.

Based on aggregated 13F filings for Q3 2024.